Approaches to gastrointestinal cytoprotection: From isolated cells, via animal experiments to healthy human subjects and patients with different gastrointestinal disorders

Current Pharmaceutical Design

Volumn 17, Issue 16, 2011, Pages 1556-1572

  Mózsik, Gyula ^a   Szabó, Imre L ^a   Czimmer, József ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Animal experiments; Different compounds; Gastrointestinal cytoprotection; Human observations; Isolated cells

Indexed keywords

2,4 DINITROPHENOL; ADRENALIN; ATROPINE; BETA CAROTENE; BETA CRYPTOXANTHIN; CAPSAICIN; CARBENOXOLONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CROMOGLYCATE DISODIUM; CYPROHEPTADINE; DACTINOMYCIN; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LYCOPENE; MANNOMUSTINE; PENTAGASTRIN; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RETINOID; RETINOL; SCOPOLAMINE; TETRACYCLINE; XANTHOPHYLL; ZEAXANTHIN;

ARTICLE; CELL ISOLATION; CELL PROTECTION; CELL VIABILITY; DRUG URINE LEVEL; DUODENUM ULCER; GASTROINTESTINAL DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH HEMORRHAGE; STOMACH ULCER; TREATMENT DURATION; ULCER HEALING; VAGOTOMY; VAGUS NERVE;

ANIMALS; CYTOPROTECTION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; RATS;

EID: 79960019633     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197016     Document Type: Article

References (76)

1. Robert A, Nezamis JE, Lancaster C, Hanchar A. Cytoprotection byprostaglandins in rats. Prevention of gastric necrosis produced byalcohol, HCl, NaOH, hypertonic NaCl, and thermal injury, Gastroenterology 1979; 77: 433-43
2. Guth PH, Aures D, Paulsen G. Topical aspirin plus HCL gastriclesions in the rat. Cytorpotective effect of prostaglandin,cymetidine and probanthine. Gastroenterology 1979; 76: 88-93.
3. Mózsik Gy, Jávor T, Dobi S. Clinical pharmacological analysis oflong term parasympatholytic treatment. In: Magyar, I. (Ed.) ActaTertii Conventus Medicinae Internae Hungarici. Gastroenterologia,Magyar, I. (Ed), pp. 709-715. Akadémiai Kiadó, Budapest, 1965
4. Gustfson J, Welling D. No acid, no ulcer - 100 years later: Areview of the history of peptic ulcer disease. J Am Coll Surg 2010;210: 110-16.
5. Mózsik Gy, Jávor T, Dobi S, Petrássy K, Szabó A. Development of "pharmacological denervation phenomenon" in patients treatedwith atropine. Eur J Pharmacol 1967; 1: 391-5.
6. Mózsik Gy, Jávor T. Development of drug cross-tolerance inpatients treated chronically with atropine. Eur J Pharmacol 1969; 6:169-74.
7. Tárnok F, Jávor T, Mózsik Gy, et al. A prospective multiclinicalstudy comparing the effects of placebo, carbenoxolone, atropine,cimetidine in patients with duodenal ulcer. Drugs Exp Clin Res 1979; 5: 157-66
8. Szabo S, Trier SJ, Frankel PW. Sulfhydryl compounds may mediategastric cytoprotection. Science 1981; 214: 200-2
9. Rainsford KD, Whitehouse MW. Gastro-protective and antiinflammatoryproperties of Green-lipped Mussel preparation (Pernacanaliculus). Arzneim Forsch 1980; 30: 2128-32.
10. Rainsford KD, Dieppe PA, Pritchard MH, et al. Protection fromgastrointestinal side-effects by related drugs in rats by lithium saltsand sodium thiocyanate. Toxicol Appl. Pharmacol 1991; 68: 323-7
11. Bjarnason I, Smethurst P, Macpherson A, et al. Glucose and citratereduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992; 102: 1546-50.
12. Rainsford KD, Whitehouse MW. Biochemical gastro-protectionfrom acute ulceration Induced by Aspirin and related drugs. BiochemPharmacol 1980; 29: 1281-1289.
13. Whitehouse MW, Rainsford KD. Prevention of Gastrotoxicity ofAspirin and related drugs in rats by lithium salts and sodium thiocyanate. Toxicol Appl Pharmacol 1983; 68: 323-7.
14. Whitehouse MW, Rainsford KD, Taylor RM, Vernon-Roberts B. Zinc Monoglycerolate: a slow-release source of zinc with antiarthriticactivity in rats. Agents and Actions 1990; 31: 47-58.
15. Rainsford KD. Reactions of the gastric mucosa to orally administeredcopper and other metal complexes. Agents and Actions 1980:Suppl. 8: 369-87.
16. Rainsford KD. The biochemical protective mechanisms againstnon-steroidal anti-inflammatory drug Induced GI mucosal damage. Acta Physiol Hung 1989; 72: 261-78.
17. ®], on the gastro-intestinal mucosalof Rodents. Exptl Clinical Gastroenterol 1992; 1: 349-60.
18. Jávor T, Bata M, Kutor, G, et al. Gastric mucosal resistance tophysical and chemical stress. In: Advances in Physiological Sciences. Vol. 29. Gastrointestinal Defefense Mechanisms, MózsikGy, Hänninen O, Jávor T. (Eds), pp. 141-159. Pergamon Press, Oxford- Akadémiai Kiadó, Budapest 1981
19. Jávor T, Bata M, Lovász L, et al. Gastric cytoprotective effect ofvitamin A and ot her carotenoids. Int J Tiss React 1983; 5: 89-296.
20. Morón F, Pena C, Cuesta E, Mózsik Gy, Jávor T. Comparativestudy of the cytoprotective effects of anticholinergic agents on thegastric mucosal lesions produced by intragastric administration of0. 6 M HCl in rats. Acta Physiol Hung 1984; 64: 247-52.
21. Nagy L, Mózsik Gy, Feledi É, Ruzsa Cs, Vezekényi Zs, Jávor T. Gastric microbleeding measurements during one day treatment indomethacinplus sodium-salycilate (1: 10) in patients. Acta PhysiolHung 1984; 64: 373-7.
22. Patty I, Benedek Sz, Deák G, et al. Controlled trial of vitamin Atherapy in gastric ulcer. The Lancet 1982; II: 876.
23. Patty I, Benedek Sz, Deák G, et al. Cytoprotective effect of vitaminA and its clinical importance in the treatment of patients withchronic gastric ulcer. Int J Tiss React 1983; 5: 301-7.
24. Szabo S. "Gastric cytoprotection" - gastroprotection: 1979-2009and beyong. J Physiol Pharmacol 2009; 60 Suppl. 2: 96
25. Mózsik Gy. Gastric cytoprotection 30 years after its discovery by André Robert: a personal perspective. Inflammo pharmacology 2010; 18: 209-21
26. Chaudhury TK, Jacobson ED. Prostaglandin cytoprotection ofgastric mucosa, Gastroenterology 1978; 74: 58-63.
27. Bódis B, Karádi O, Abdel-Salam OME, Vörös S, Nagy L, Mózsik Gy. Direct cellular effect of Helicobacter pylori alone and withcotreatments of ethanol and indomethacin in mixed isolated rat gastricmucosa cells. Dig Dis Sci 1996; 41: 430.
28. Bódis B, Karádi O, Nagy L, Dohoczky C, Kolega M, Mózsik Gy. Direct cellular effects of some mediators, hormones and growthfactor-like agents on denervated (isolated) rat gastric mucosal cells, J Physiol Paris 1997; 91: 183-7.
29. Bódis B, Karádi O, Németh P, Dohoczky C, Kolega M, Mózsik G. Evidence for direct cellular protective effect of PL-10 substances(synthesized parts of body protection compound, BPC) and theirspecificity to gastric mucosal cells. Life Sci 1997; 61: 243-8.
30. Bódis B, Németh P, Mózsik Gy. Organoprotection and Cytoprotectionin the Stomach. Akadémia Kiadó, Budapest, Hungary 1998
31. Bódis B, Karádi O, Szabó I, Németh P, Belágyi J, Mózsik Gy. Evidence for the involvement of oxygen free radicals in the ethanol-induced late cellular injury in mouse myeloma cells. J PhysiolParis 2000; 94: 67-70.
32. Garamszegi M, Jávor T, Sütö G, Vincze Á, Tóth Gy, Mózsik Gy. Effect of atropine, PGF2 alpha and cimetidine on the beta-caroteneinduced cytoprotection in ethanol-treated rats. Acta Physiol Hung 1989; 73: 221-4.
33. Moron F, Jávor T, Bata M, Fiegler M, Mózsik Gy. The relationshipsbetween indomethacin-induced gastric ulcer, ulcer protectionby cimetidine and prostacyclin and the cAMP system of the gastricfundic mucosa in the rat. Acta Physiol Acad Sci Hung 1982; 60:149-53.
34. Mózsik Gy, Lovász L, Kutor G, Nagy L, Tárnok F. Experimentalevidence for cytoprotective effect of atropine on the rat gastric mucosa, Acta Med Acad Sci Hung 1980; 37: 401-5.
35. Jávor T, Bata M, Lovász L, et al. Gastric cytoprotective effects ofvitamin A and other carotenoids. Int J Tiss React 1983; 5: 289-96.
36. Mózsik Gy, Moron F, Fiegler M, et al. Interrelationships betweenmembrane-bound ATP-dependent energy systems, gastric mucosaldamage produced by NaOH, hypertonic NaCl, HCl, and alcohol,and prostacyclin-induced gastric cytoprotection in rats, Prostaglandins Leukotr Med 1983; 12: 423-36.
37. Moron F, Mózsik Gy, Nagy L, Patty I, Tárnok F, Jávor T. Evidencefor the existence of gastric cytoprotective effect of atropine and cimetidinein humans. Acta Physiol Hung 1984; 65: 367-72.
38. Mózsik Gy, Moron F, Nagy L, Ruzsa Cs, Tárnok F, Jávor T. Evidence of the gastric cytoprotective effects of vitamin A, atropineand cimetidine on the development of gastric mucosal damageproduced by administration of indomethacin in healthy subjects, IntJ Tiss React 1986; 8: 85-90.
39. Mózsik Gy. Neural, hormonal and pharmacological regulations ofretinoids-induced gastrointestinal mucosal protection, Recent ResDevel Life Sci 2005; 3: 131-207
40. Mózsik Gy. Molecular pharmacology and biochemistry of gastroduodenalmucosal damage and protection. In: Discoveries in Gastroenterology.From Basic Research the Clinical Perspectives (1960-2005), Mózsik, Gy. (Ed), pp. 139-224. Akadémiai Kiadó,Budapest 2006
41. Rumi Gy. Jr, Matus Z, Tóth G, et al. Changes of serum carotenoidsin patients with esophageal, gastric, hepatocellular, pancreaticand colorectal cancer, J Physiol Paris 2001; 95: 239-42.
42. Rumi Gy. jr, Pár A, Matus Z, Rumi Gy, Mózsik Gy. The DefensiveEffects of Retinoids in the Gastrointestinal Tract, (Animal Experimentsand Human Observations). Akadémia Kiadó, Budapest,Hungary 2001
43. Vincze Á, Kirély Á, Sütö G, Karádi O, Mózsik Gy. Role of neurohumoraland local mucosal factors in β-carotene-induced gastroprotectionin the rat, In: Twenty Five Years of Peptic Ulcer Researchin Hungary. From Basic Science to Clinical Practice 1975-1995, Mózsik, Gy, Nagy, L, Király, Á. (Eds), pp. 275-85. AkadémiaKiadó, Budapest, Hungary.
44. Mózsik, Gy, Nagy Z, Nagy A, et al. Leiden mutation (as genetic)and environmental (retinoids) sequences in the acute and chronicinflammatory and premalignant colon disease in human gastrointestinaltract, J Physiol Paris 2001; 95: 489-94.
45. Mózsik Gy, Rumi Gy, Dömötör A, et al. Involvement of serumretinoids and Leiden mutation in patients with esophageal, gastric,liver, pancreatic, and colorectal cancers in Hungary, World J Gastroenterol 2005; 11: 7646-50.
46. Mózsik Gy, Dömötör A, Rumi Gy, Szekeres Gy. Gastrointestinalcytoprotection: from basic science to clinical perspectives. Inflammo pharmacology 2005; 15: 49-60. I
47. Szabó I, Bódis B, Nagy L, Mózsik Gy. Comparative studies onisolated mucosal mexed cells and hepatoma, myeloma cell lineswith ethanol, indomethacin and their combinations. Inflammopharmacology 1997; 5: 83-91.
48. Szabó I, Bódis B, Németh P, Mózsik Gy. Usage of scavengers onstable cultured (SP2/0-AG14 and HEP G2) cell lines as an approachto reveal the mechanisms of cytoprotection, In: Twenty FiveYears of Peptic Ulcer Research in Hungary. From Basic Science toClinical Practice 1975-1995, Mózsik, Gy, Nagy, L, Király, Á.(Eds), pp. 275-85. Akadémia Kiadó, Budapest, Hungary 1997
49. Szabó I, Rumi Gy, Bódis B, Németh P, Mózsik Gy. Gastrin andpentagastrin enhance the tumour proliferation of human stable culturedgastric adenocarcinoma cells, J Physiol Paris 2000; 94: 71-74.
50. Nagy L, Szabó S, Morales RE, Plebani M, Jenkins JM. Identificationof subcellular targets and sensitive tests of ethanol-induceddamage in isolated rat gastric mucosal cells. Gastroenterology 1994; 107: 907-14.
51. Szabó I, Bódis B, Nagy L, Mózsik Gy. Comparative studies ofisolated gasrtic mucosa mixed cells and hepatoma and myelomacell lines with ethanol indomethacin, and their combination, In flammopharmacology 1996.
52. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide,BPC. An overview of the stomach-stress-organoprotection hypothesisand beneficial effects of BPC. J Physiol Paris 1993; 87:313-27.
53. Sikirić P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotectionand adaptive cytoprotection and stable gastric pentadecapeptideBPC 157. Possible significance and implacations for novelmediator. Curr Pharm Des 2010; 16: 1214-23.
54. Baur H, Kasperek S, Pfaff E. Criteria of viability of isolated livercells. Z Physiol Chem 1975; 356: 827-38.
55. Bergmeyer HU. and Bern TE. Colorimetric assay with L(+) lactate,NAD, phenazone, methosulphate and INT, in: Methods in EnzymaticAnalysi,. Bergmeyer HU (Ed.) pp: 579-582, AkademicPress, New York, USA 1974
56. Mosmann T. Rapid colorimetric assay for cellular growth andsurvival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
57. Dey CS. and Majumder GC. A simple quantitative method ofestimation of cell intactsness based on ethidium bromide fluorescens. Biochem Int 1989; 17: 367-74.
58. Shay H, Komarov SA, Fels SS, Meranze D, Gurenstein M, Siplet H. A imple method for the uniform production of gastric ulcerationin the rat, Gastroenterology 1945; 5: 46-61.
59. Mózsik Gy, Jávor T. A biochemical and pharmacological approachto the genesis of ulcer disease. I. A model study of ethanol-inducedinjury to gastric mucosa in rats Dig Dis Sci 1988; 33: 92-105.
60. Mózsik Gy, Jávor T. Therapyof ulcers with sulfhydryl and nonsulfhydrylantioxidants. In: Ulcer Disease, Investigation and Basis for Therapy Schwabb E. and Szabó S. (Eds), pp. 321 Marcel Dekker,New York, USA 1991
61. Mózsik Gy, Király Á, Garamszegi M, et al. Failure of prostacyclin,beta-carotene, atropine and cimetidine to produce gastric cyto- andgeneral mucosal protection in surgically vagotomized rats, Life Sci 1991; 49: 1383-9.
62. Karádi O, Mózsik Gy. Surgical and Chemical Vagotomy on theGastrintestinal Mucosal Defense. Akadémia Kiadó, Budapest,Hungary 2000
63. Nagy L, Mózsik Gy, Feledi E, Ruzsa C, Vezekenyi Z., Jávor T. Gastric microbleeding measurements during one day treatmentwith indomethacin and indomethacin plus sodium salicylate (1:10) in patients, Acta Physiol Hung 1984; 64: 373-7.
64. Mózsik Gy, Szolcsányi J, Rácz I. Gastroprotection induced bycapsaicin in healthy human subjects, World J Gastroenterol 2005;11: 5180-4.
65. Mózsik Gy, Moron F, Jávor T. Cellular mechanisms of the developmentof gastric mucosal damage and of gastrocytoprotection inducedby prostacyclin in rats. A pharmacological study, ProstaglandinsLeukotr Med 1982; 9: 71-84.
66. Miller TA. Protective effects of prostaglandins against gastricmucosal damage: current knowledge and proposed mechanisms Am J Physiol Gastrointest Liver Physiol 1983; 245: G601-23.
67. Szolcsányi J. Capsaicin and neurogenic inflammation: history andearly findings.: in: Chahl LA, Szolcsányi J, Lembeck F. (Eds.) Antidromic Vasodilatation and Neurogenic Inflammation, ChahlLA, Szolcsányi J, Lembeck F. (Eds), pp. 27-56. Akadémiai Kiadó, Budapest 1984.
68. Mózsik Gy, Abdel-Salam OME, Szolcsányi J. Capsaicin-SensitiveAfferent Nerves in Gastric Mucosal Damage and Protection. Akadémiai Kiadó, Budapest 1997.
69. Mózsik Gy, Szolcsányi J, Dömötör A. Capsaicin research as a newtool to approach of the human gastrointestinal physiology, pathologyand pharmacology. Inflammopharmacology 2007; 15: 232-45
70. Mózsik Gy, Dömötör A, Past T, et al. Capsaicinoids: from thePlant Cultivation to the Production of the Human Medical Drug. Akadémiai Kiadó, Budapest 2009.
71. Mózsik Gy, Past T, Dömötör A, Kuzma M, Perjési P. Production oforally applicable new drug or drug combinations from natural origincapsaicinoids for human medical therapy. Curr: Pharm Des 2010; 16: 1197-208.
72. Mózsik Gy, Pár A, Bertelli A, (Eds.) Recent Advances in GastrointestinalCytoprotection. Akadémiai Kiadó, Budapest 1984
73. Mózsik Gy, Jávor T, Kitajima M, et al. (Eds) Advances in GastrointestinalCytoprotection: Topics 1987. Akadémiai Kiadó, Budapest 1989.
74. Mózsik Gy, Pár A, Csomós G, et al. (Eds) Cell Injury and Protectionin the Gastrointestinal Tract: from Basic Sciences to Clinical Perspectives. Akadémiai Kiadó, Budapest 1993.
75. Mózsik Gy, Nagy L, Pár A, Rainsford KD. (Eds.) Cell Injury andProtection in the Gastrointestinal Tract. Kluwer Academic Publishers.Dordrecht, Boston, London 1997.
76. Mózsik Gy, Pfeiffer CJ, Czimmer J. (Guest Editors) Injury andProtection in the Gastrointestinal Tract J Physiol Paris, 2002; 95: 1-494.